PDF(Pubmed)
Abstract：
UNASSIGNED: Non-small cell lung cancer (NSCLC) stands as one of the most prevalent types of cancer worldwide, driving extensive research in oncologic therapeutic approaches. Atezolizumab, among the treatments under scrutiny, is undergoing evaluation as a potential first-line therapy for NSCLC. This review aims to assess the efficacy of atezolizumab in treating patients with NSCLC and to shed light on the ongoing quest for the most effective treatment.
UNASSIGNED: Multiple scientific databases, including PubMed, Cochrane, and ScienceDirect, were consulted. The literature identification utilized the strategic Boolean term method of keywords relating to \"non-small cell lung cancer\" and \"atezolizumab\" to suggest the analyzed population in our review without restricting the potential outcomes. The primary inclusion criterion is clinical studies that attempted to determine the efficacy of atezolizumab in NSCLC patients.
UNASSIGNED: We included four trials to be analyzed in the final analysis, which we stratified into the programmed cell death-ligand 1 (PD-L1) expressivity status aside from the pooled intention-to-treat (ITT) population. We found the addition of atezolizumab may significantly improve the overall survival (OS) in the respective arm, remarkably among the high PD-L1 expression group (TC3 or IC3). The result of our meta-analysis presented the pooled OS of 0.79 (0.72, 0.87) in 95% confidence interval (CI) with a P value of < 0.05. Sub-analysis of the PD-L1\'s expression revealed TC3 population benefits the most (hazard ratio (HR): 0.55, 95% CI (0.42, 0.73)), compared to low (HR: 0.80, 95% CI (0.68, 0.93)) and negative expression (HR: 0.79, 95% CI (0.68, 0.93)); which is statistically meaningful (P < 0.05). Similar result was also observed in progression-free survival (PFS) analysis with the HR value of 0.63 (0.55, 0.72), with P value of < 0.05, favoring atezolizumab arm.
UNASSIGNED: Upon examination, the study reveals that the addition of atezolizumab demonstrates notable improvements in both OS and PFS among NSCLC patients. These findings present promising attributes for atezolizumab as a viable treatment for NSCLC. However, it is important to acknowledge that the future holds further revelations in this realm, and more insights are yet to be uncovered.
UNASSIGNED: Multiple scientific databases, including PubMed, Cochrane, and ScienceDirect, were consulted. The literature identification utilized the strategic Boolean term method of keywords relating to \"non-small cell lung cancer\" and \"atezolizumab\" to suggest the analyzed population in our review without restricting the potential outcomes. The primary inclusion criterion is clinical studies that attempted to determine the efficacy of atezolizumab in NSCLC patients.
UNASSIGNED: We included four trials to be analyzed in the final analysis, which we stratified into the programmed cell death-ligand 1 (PD-L1) expressivity status aside from the pooled intention-to-treat (ITT) population. We found the addition of atezolizumab may significantly improve the overall survival (OS) in the respective arm, remarkably among the high PD-L1 expression group (TC3 or IC3). The result of our meta-analysis presented the pooled OS of 0.79 (0.72, 0.87) in 95% confidence interval (CI) with a P value of < 0.05. Sub-analysis of the PD-L1\'s expression revealed TC3 population benefits the most (hazard ratio (HR): 0.55, 95% CI (0.42, 0.73)), compared to low (HR: 0.80, 95% CI (0.68, 0.93)) and negative expression (HR: 0.79, 95% CI (0.68, 0.93)); which is statistically meaningful (P < 0.05). Similar result was also observed in progression-free survival (PFS) analysis with the HR value of 0.63 (0.55, 0.72), with P value of < 0.05, favoring atezolizumab arm.
UNASSIGNED: Upon examination, the study reveals that the addition of atezolizumab demonstrates notable improvements in both OS and PFS among NSCLC patients. These findings present promising attributes for atezolizumab as a viable treatment for NSCLC. However, it is important to acknowledge that the future holds further revelations in this realm, and more insights are yet to be uncovered.
摘要：
■非小细胞肺癌（NSCLC）是全球最普遍的癌症之一。推动肿瘤治疗方法的广泛研究。阿替珠单抗,在接受审查的治疗中，正在接受作为非小细胞肺癌潜在一线治疗的评估。这篇综述旨在评估阿特珠单抗治疗NSCLC患者的疗效，并阐明对最有效治疗的持续追求。
■多个科学数据库，包括PubMed,科克伦,和科学直接，被咨询过。文献鉴定利用与“非小细胞肺癌”和“阿特珠单抗”相关的关键词的战略性布尔术语方法，在我们的综述中建议分析人群，而不限制潜在结果。主要的纳入标准是试图确定阿特珠单抗在NSCLC患者中的疗效的临床研究。
■我们纳入了四项试验进行最终分析，除了合并的意向治疗（ITT）群体外，我们将其分层为程序性细胞死亡配体1（PD-L1）表达状态。我们发现添加阿特珠单抗可以显着改善相应组的总生存期（OS），在PD-L1高表达组(TC3或IC3)中显著。我们的荟萃分析结果显示，在95％置信区间（CI）中，合并的OS为0.79（0.72，0.87），P值<0.05。对PD-L1表达的亚分析显示TC3群体受益最大(风险比(HR):0.55,95%CI(0.42,0.73)),比较低(HR:0.80,95%CI(0.68,0.93))和阴性表达(HR:0.79,95%CI(0.68,0.93));具有统计学意义(P<0.05)。在无进展生存期（PFS）分析中也观察到类似的结果，HR值为0.63（0.55，0.72），P值<0.05，有利于阿替珠单抗组。
■经检查，该研究显示,在NSCLC患者中,添加阿特珠单抗证明OS和PFS均有显著改善.这些发现为阿司珠单抗作为NSCLC的可行治疗提供了有希望的属性。然而,重要的是要承认未来在这个领域有进一步的启示，还有更多的见解有待发现。
■多个科学数据库，包括PubMed,科克伦,和科学直接，被咨询过。文献鉴定利用与“非小细胞肺癌”和“阿特珠单抗”相关的关键词的战略性布尔术语方法，在我们的综述中建议分析人群，而不限制潜在结果。主要的纳入标准是试图确定阿特珠单抗在NSCLC患者中的疗效的临床研究。
■我们纳入了四项试验进行最终分析，除了合并的意向治疗（ITT）群体外，我们将其分层为程序性细胞死亡配体1（PD-L1）表达状态。我们发现添加阿特珠单抗可以显着改善相应组的总生存期（OS），在PD-L1高表达组(TC3或IC3)中显著。我们的荟萃分析结果显示，在95％置信区间（CI）中，合并的OS为0.79（0.72，0.87），P值<0.05。对PD-L1表达的亚分析显示TC3群体受益最大(风险比(HR):0.55,95%CI(0.42,0.73)),比较低(HR:0.80,95%CI(0.68,0.93))和阴性表达(HR:0.79,95%CI(0.68,0.93));具有统计学意义(P<0.05)。在无进展生存期（PFS）分析中也观察到类似的结果，HR值为0.63（0.55，0.72），P值<0.05，有利于阿替珠单抗组。
■经检查，该研究显示,在NSCLC患者中,添加阿特珠单抗证明OS和PFS均有显著改善.这些发现为阿司珠单抗作为NSCLC的可行治疗提供了有希望的属性。然而,重要的是要承认未来在这个领域有进一步的启示，还有更多的见解有待发现。
